We are live on ! Find out more
IMUC.WS

ImmunoCellular Therapeutics Ltd.
IMUC.WS

Delisted

IMUC.WS was delisted on the 16th of October, 2018.

Back to rankings

4 hedge funds and large institutions have $480K invested in ImmunoCellular Therapeutics Ltd. in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$130K
2
AFM
Anson Funds Management
Texas
+$39.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$31.9K
4
UBS Group
UBS Group
Switzerland
+$416

Top Sellers

No sellers this quarter

IMUC.WS Hedge Fund Activity: Q4 2016 in Review

4 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q4 2016, worth a combined $480K.

Buyers outnumbered sellers: 4 funds opened new IMUC.WS positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $130K.

  • 4 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q4 2016, up from 0 in Q3 2016.
  • Funds reported $480K of ImmunoCellular Therapeutics Ltd. stock for Q4 2016.
  • 4 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q4 2016 and 0 closed out, a net change of +4 holders.
  • The largest ImmunoCellular Therapeutics Ltd. buyer in Q4 2016 was Sabby Management, an estimated $130K added.

Based on aggregated 13F filings for Q4 2016.